NCT03906643: HS-201, an HSP90 Inhibitor-linked Verteporfin for Detection of Solid Malignancies

NCT03906643
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 99 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patient must be able to return to Duke University Medical Center for adequate follow-up, as required by this protocol
Exclusions: 
https://ClinicalTrials.gov/show/NCT03906643

Comments are closed.

Up ↑